Skip to content

BioNexus Gene Lab Corp.: 10-Q filed 2021-11-15

What BioNexus Gene Lab Corp. reported in its quarterly report filed 2021-11-15 (fiscal Q3 2021): 30 published measures, 86 facts as tagged in accession 0001477932-21-008128.

This filing

Form
10-Q (quarterly report)
Filed
2021-11-15
Fiscal period
fiscal Q3 2021
Accession
0001477932-21-008128 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BioNexus Gene Lab Corp. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2021-09-309,765,004USD
At 2020-12-3110,115,293USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2021-09-302,713,398USD
At 2020-12-313,453,139USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2021-09-307,051,606USD
At 2021-06-306,813,224USD
At 2021-03-316,792,430USD
At 2020-12-316,662,154USD
At 2020-09-306,682,462USD
At 2020-06-306,199,934USD
At 2020-03-316,192,217USD
At 2019-12-311,122,364USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2021-09-301,700,396USD
At 2020-12-312,787,692USD
At 2020-09-302,190,072USD
At 2019-12-31859,076USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2021-07-01 to 2021-09-30295,322USD92
2021-01-01 to 2021-09-30662,328USD273
2021-04-01 to 2021-06-3028,262USD91
2021-01-01 to 2021-03-31338,744USD90
2020-07-01 to 2020-09-30234,458USD92
2020-01-01 to 2020-09-301,268,261USD274
2020-01-01 to 2020-03-311,069,644USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2021-01-01 to 2021-09-30-473,846USD273
2020-01-01 to 2020-09-30-379,802USD274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2021-01-01 to 2021-09-301,883USD273
2020-01-01 to 2020-09-30305USD274

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2021-07-01 to 2021-09-303,575,966USD92
2021-01-01 to 2021-09-3010,117,296USD273
2020-07-01 to 2020-09-303,091,012USD92
2020-01-01 to 2020-09-307,264,554USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2021-01-01 to 2021-09-30-23,263USD273
2020-01-01 to 2020-09-30-7,203USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2021-01-01 to 2021-09-30-414,285USD273
2020-01-01 to 2020-09-301,736,495USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2021-09-301,423,115USD
At 2020-12-31760,787USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2021-07-01 to 2021-09-30-75,169USD92
2021-01-01 to 2021-09-30-183,449USD273
2020-07-01 to 2020-09-30-492USD92
2020-01-01 to 2020-09-30-1,839USD274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2021-09-301,647,359USD
At 2020-12-311,785,602USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2021-07-01 to 2021-09-30372,641USD92
2021-01-01 to 2021-09-30854,764USD273
2020-07-01 to 2020-09-30237,306USD92
2020-01-01 to 2020-09-301,276,862USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2021-09-307,402,248USD
At 2020-12-317,985,494USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2021-09-302,664,823USD
At 2020-12-313,373,598USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2021-09-301,487,680USD
At 2020-12-311,176,170USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2021-07-01 to 2021-09-30688,099USD92
2021-01-01 to 2021-09-301,738,271USD273
2020-07-01 to 2020-09-30522,222USD92
2020-01-01 to 2020-09-301,336,819USD274

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2021-07-01 to 2021-09-302,887,867USD92
2021-01-01 to 2021-09-308,379,025USD273
2020-07-01 to 2020-09-302,568,790USD92
2020-01-01 to 2020-09-305,927,735USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2021-09-30171,218,152shares
At 2020-12-31171,218,152shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2021-09-30-5,011,891USD
At 2020-12-31-5,011,891USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2021-09-30-139,192USD
At 2020-12-31133,684USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2021-09-3044,615USD
At 2020-12-3162,529USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2020-04-01 to 2020-06-30-35,841USD91

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2021-07-01 to 2021-09-30238,382USD92
2021-01-01 to 2021-09-30389,452USD273
2020-07-01 to 2020-09-30482,528USD92
2020-01-01 to 2020-09-301,265,193USD274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2021-07-01 to 2021-09-30362,306USD92
2021-01-01 to 2021-09-301,043,271USD273
2020-07-01 to 2020-09-30294,005USD92
2020-01-01 to 2020-09-30839,415USD274

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2021-01-01 to 2021-09-3068,488USD273
2020-01-01 to 2020-09-3030,567USD274

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2021-01-01 to 2021-09-308,987USD273
2020-01-01 to 2020-09-306,762USD274

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2021-01-01 to 2021-09-30-94,373USD273
2020-01-01 to 2020-09-30-82,348USD274

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2021-01-01 to 2021-09-30-311,509USD273
2020-01-01 to 2020-09-30125,267USD274

Inspect the source

Entity
BioNexus Gene Lab Corp. / CIK 0001737523
Captured
2026-09-21T17:25:37.348Z
SEC response SHA-256
eebcf668b9e42f0c31bf1fe5b3c17450d7f4d836f715c9cebcc6a4fafbcff983

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001737523.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))